Abstract: Slide Presentations |

Health-Related Quality of Life (QoL) in Patients With Chronic Sarcoidosis Treated With Methotrexate FREE TO VIEW

Violeta V. Vucinic, MD, PhD; Jelica L. Videnovic; Vladimir V. Zugic; Branislav S. Gvozdenovic
Author and Funding Information

Institute of Pulmonary Diseases, Belgrade, Yugoslavia


Chest. 2003;124(4_MeetingAbstracts):113S. doi:10.1378/chest.124.4_MeetingAbstracts.113S-b
Text Size: A A A
Published online


PURPOSE:  In this study we evaluated the QOL in sarcoidosis patients treated with methotrexate employing a general QOL measure, the World Health Organization Quality of Life assessment instrument – WHOQOL- 100.PATIENTS: 72 sarcoidosis patients from the institute of pulmonary diseases, department of sarcoidosis were studied.None of the participating patients had any medical history, which might influence their quality of life patients with comorbidity were excluded. (diabetes, hypertension).The mean time from diagnosis for the whole group of sarcoidosis patients was 3.5 years. The analyzed group was homogeneous according to their demographic characteristics, observing the residence and the life style.Patients were divided into the two groups according to the therapy. Group I patients treated with methotrexate and Group II sarcoidosis patients without any treatment.The hypothesis was that sarcoidosis patients treated with methotrexate due to the serious chronic form of the disease have worse quality of life.All analyses were performed using the Statistical Package for Social Science version10 (SPSS 10).

RESULTS:  Analyzing the questions under G 2 (G2.1) and G3 (G2.2) T test for equality of means (Sig. 2 tailed = 0.55) there was no statistical significance between the two groups.The fact that makes the statistically significant difference: T test for equality of means (Sig. 2-tailed = 0.003) between the group treated with methotrexate and not treated sarcoidosis patients is the general question G4 (G2.3) and the general question G1.2.

CONCLUSION:  Although with severe chronic sarcoidosis, treated with methotrexate as a cytotoxic drug, these patients do not have an impression of the worst quality of life than the group of sarcoidosis patients that do not require any treatment at the time of answering the questionnaire.

CLINICAL IMPLICATIONS:  The treatment with cytotoxic drug, due to the chronic form of the disease, does not influence their general quality of life in the analyzed sarcoidosis patients.

DISCLOSURE:  V.V. Vucinic, None.

Tuesday, October 28, 2003

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543